Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias

Area of Science:

• Cardiology
• Pharmacology
• Metabolic Disorders

Background:

• Primary mixed hyperlipidemia poses risks for atherosclerotic vascular disease.
• Diet and single-drug therapies often fail to achieve optimal lipid targets.
• Combination therapy may be necessary for managing complex hyperlipidemia.

Purpose of the Study:

• To evaluate the safety and efficacy of long-term gemfibrozil-lovastatin combination therapy.
• To assess lipid profile changes in patients with primary mixed hyperlipidemia.
• To monitor liver function and creatine phosphokinase levels during combination therapy.

Main Methods:

• Retrospective, observational study of 80 patients with primary mixed hyperlipidemia.
• Long-term (21 months/patient) open-label gemfibrozil (1.2 g/day) and lovastatin treatment.
• Regular monitoring of liver function tests and creatine phosphokinase levels.

Main Results:

• Significant reductions in total cholesterol (-22%), triglycerides (-35%), LDL cholesterol (-26%), and total cholesterol/HDL ratio (-24%) (p ≤ 0.0001).
• Excellent safety profile with only 1 abnormal liver function test (0.02%) and 1 creatine phosphokinase elevation ≥ 3x upper limit (0.1%).
• Myositis occurred in 3% of patients, leading to discontinuation in some; no rhabdomyolysis or myoglobinuria reported.

Conclusions:

• Gemfibrozil-lovastatin combination therapy is effective in improving lipid profiles for patients with primary mixed hyperlipidemia.
• The combination demonstrates a favorable safety profile regarding liver function and muscle enzyme elevation.
• Careful monitoring is warranted due to the potential for myositis in a small subset of patients.